Top

Published in:

01-01-2011 | Original Article

Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation

Authors: Shohei Yamamoto, Hirokazu Ikeda, Daisuke Toyama, Mayumi Hayashi, Kousuke Akiyama, Manabu Suzuki, Yutaka Tanaka, Tsuneki Watanabe, Yoko Fujimoto, Ichirou Hosaki, Hirokazu Nishihira, Keiichi Isoyama

Published in: International Journal of Hematology | Issue 1/2011

Abstract

The aim of this study was to evaluate the quality of long-term cryopreserved umbilical cord blood (CB) units for hematopoietic cell transplantation (HCT). The recovery of the number of total nucleated cell (TNC), hematopoietic progenitor cells (HPCs; CD34+ cells, colony-forming units-granulocyte/macrophages [CFU-GMs]), and the percentage of viable cells, CD34+ CD38− cells, and CD34+ CXCR4+ cells of CB units cryopreserved for 10 years for HCT were examined. Eighteen CB units cryopreserved for 10 years (as the study group) and for 1 month (as the control group), respectively, were analyzed. The recovery rate of TNC, CD34+ cells and CFU-GMs were 88.72 ± 16.40, 68.39 ± 18.37 and 42.28 ± 38.16% for the study group and 80.17 ± 14.46, 72.67 ± 20.38 and 49.61 ± 36.39% for the control group (p = 0.106, p = 0.513 and p = 0.559, respectively). There were no significant differences in the recovery rate of TNC, CD34+ cells and CFU-GMs between the study group and the control group. The mean basal percentage of viable cells, CD34+ CD38− cells, and CD34+ CXCR4+ cells after thawing were 83.69 ± 9.45, 9.11 ± 4.13 and 81.65 ± 10.82% for the study group. These results indicate that long-term cryopreservation does not negatively affect the quality of CB units for HCT.

Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–8.PubMed

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.CrossRefPubMed

Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–85.CrossRefPubMed

Laroche V, McKenna DH, Moroff G, Schierman T, Kadidlo D, McCullough J. Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion. 2005;45:1909–16.CrossRefPubMed

Timeus F, Crescenzio N, Saracco P, Doria A, Fazio L, Albiani R, et al. Recovery of cord bloos hematopoietic progenitors after successive freezing and thawing procedures. Haematologica. 2003;88:74–9.PubMed

Solves P, Mirabet V, Planelles D, Carbonell-Uberos F, Roig R. Influence of volume reduction and cryopresrvation methodologies on quality of thawed umbilical cord blood units for transplantation. Cryobiology. 2008;56:152–8.CrossRefPubMed

Minegishi M, Itoh T, Fukawa N, Kitaura T, Miura J, Takahashi H, et al. Quality of umbilical cord blood CD34+ cells in a double-compartment freezing bag cryopreserved without a rate-controlled programmed freezer. Int J Hematol. 2007;85:78–84.CrossRefPubMed

Beshlawy AE, Metwally HG, Khalek KA, Hammoud RF, Mousa SM. The effect of freezing on the recovery and expansion of umbilical cord blood hematopoietic stem cells. Exp Clin Transplant. 2009;7:50–5.PubMed

Meyer TP, Hofmann B, Zaisserer J, Jacobs VR, Fuchs B, Rapp S, et al. Analysis and cryopreservation of hematopoietic stem and progenitor cells from umbilical cord blood. Cytotherapy. 2006;8:265–76.CrossRefPubMed

10.

Solves P, Mirabet V, Carbonell-Uberos F, Soler A. CD34+ cell content before freezing represents the hematopoietic stem cell content of thawed and washed cord blood units. Transfusion. 2005;45:116–7.CrossRefPubMed

11.

Koliakos G, Alamdari DH, Tsagias N, Kouzi-Koliakos K, Michaloudi E, Karagiannis V. A novel high-yield volume-reduction method for the cryopreservation of UC blood units. Cytotherapy. 2007;9:654–9.CrossRefPubMed

12.

Harris DT, Schumacher MJ, Rychlik S, Booth A, Acevedo A, Rubinstein P, et al. Collection, separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant. 1994;13:135–43.PubMed

13.

Broxmeyer HE, Cooper S. High-efficiency recovery of immature haematopoietic progenitor cells with extensive proliferative capacity from human cord blood cryopreserved for 10 years. Clin Exp Immunol. 1997;107:45–53.PubMed

14.

Kobylka P, Ivanyi P, Breur-Vriesendorp BS. Preservation of immunological and colony-forming capacities of long-term (15 years) cryopreserved cord blood cells. Transplantation. 1998;65:1275–8.CrossRefPubMed

15.

Mugishima H, Harada K, Chin M, Suzuki T, Takagi K, Hayakawa S, et al. Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Bone Marrow Transplant. 1999;23:395–6.CrossRefPubMed

16.

Broxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, Bodine DM. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci USA. 2003;100:645–50.CrossRefPubMed

17.

Hao QL, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM. A functional comparison of CD34+ CD38− cells in cord blood and bone marrow. Blood. 1995;86:3745–53.PubMed

18.

Huang S, Terstappen LW. Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38− hematopoietic stem cells. Blood. 1994;83:1515–26.PubMed

19.

Hao QL, Smogorzewska EM, Barsky LW, Crooks GM. In vitro identification of single CD34+ CD38− cells with both lymphoid and myeloid potential. Blood. 1998;91:4145–51.PubMed

20.

Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833–5.CrossRefPubMed

21.

Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–8.CrossRefPubMed

22.

Rubinstein P, Dobria L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995;92:10119–22.CrossRefPubMed

23.

Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on ISHAGE guidelines. Cytometry. 1998;34:61–70.CrossRefPubMed

24.

Kurtberg J, Cario MS, Fraser JK, Baxter-Lowe L, Cohen G, Carter SL, et al. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion. 2005;45:842–55.CrossRef

25.

Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placenta/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000;96:2717–22.PubMed

26.

Nagamura-Inoue T, Shioya M, Sugo M, Cui Y, Takahashi A, Tomita S, et al. Wash-out of DMSO dose not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adults patients with units shipped from a single cord blood bank. Transfusion. 2003;43:1285–94.CrossRefPubMed

27.

Isoyama K, Oda M, Kato K, Nagamura-Inoue T, Kai S, Kigasawa H, et al. Long-term outcome of cord blood transplantation from unrelated donors as an initial transplantation procedure for children with AML in Japan. Bone Marrow Transplant. 2010;45:69–77.CrossRefPubMed

28.

Ogawa A, Takahashi M. Hematopoietic cell counting of cryopreserved cord blood before transplantaiton (in Japanese). Ketsueki Shuyouka. 2005;51:127–32.

29.

Yoo KH, Lee SH, Kim HJ, Sung KW, Jung HL, Cho EJ, et al. The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2007;39:512–21.CrossRef

30.

Schmid I, Hausner MA, Cole SW, Uittenbogaart CH, Giorgi JV, Jamieson BD. Simultaneous flow cytometric measurement of viability and lymphocyte subset proliferation. J Immunol Methods. 2001;247:175–86.CrossRefPubMed

31.

Humpe A, Beck C, Schoch R, Kneba M, Horst HA. Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreservation and comparison with trypan blue exclusion staining. Transfusion. 2005;45:1208–13.CrossRefPubMed

32.

Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single non-lineage committees CD34+ CD38− progenitor cells. Blood. 1991;77:1218–27.PubMed

33.

Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320–5.CrossRefPubMed

34.

Timeus F, Crescenzio N, Basso G, Ramenghi U, Saracco P, Gabutti V. Cell adhesion molecule expression in cord blood CD34+ cells. Stem Cells. 1998;16:120–6.CrossRefPubMed

35.

Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjyo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 1993;261:895–7.CrossRef

36.

Spencer A, Jackson J, Bauch-Brown C. Enumeration of bone marrow “homing” haemopoietic stem cells from G-CSF-mobilised normal donors and influence on engraftment following allogeneic transplantation. Bone Marrow Transplant. 2001;28:1019–22.CrossRefPubMed

37.

Dabusti M, Lanza F, Campioni D, Castagnari B, Tieghi A, et al. CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies. J Hematother Stem Cell Res. 2003;12:425–34.CrossRefPubMed

Title: Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation
Authors: Shohei Yamamoto
Hirokazu Ikeda
Daisuke Toyama
Mayumi Hayashi
Kousuke Akiyama
Manabu Suzuki
Yutaka Tanaka
Tsuneki Watanabe
Yoko Fujimoto
Ichirou Hosaki
Hirokazu Nishihira
Keiichi Isoyama
Publication date: 01-01-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 1/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0755-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial

Concurrent development of “Burkitt-like” lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin

Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation

Repeated donor lymphocyte infusions overcome a myeloid sarcoma of the stomach resulting from a relapse of acute myeloid leukemia after allogeneic cell transplantation in long-term survival of more than 10 years

Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation

Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer